Abstract: There are disclosed inter alia antigen pools which are useful in the treatment of cancer, particularly melanoma, especially cutaneous melanoma and uveal melanoma.

Abstract: There are disclosed inter alia fusion proteins and nucleic acids encoding said fusion proteins which are useful in the treatment and prevention of cancer, particularly melanoma, especially cutaneous melanoma and uveal melanoma.

Abstract: Provided is an anti-TNF-? antibody comprising a sequence modification that inhibits presentation of the antibody by human leukocyte antigen (HLA) molecules. The anti-TNF-? antibody may be infliximab or a fragment or variant thereof. In this case, the modification is suitably one that inhibits presentation of the antibody by DRB1*03:01, such as a modification in the region corresponding to residues 1 to 21 of SEQ ID NO: 1, or a modification in the region corresponding to residues 145 to 159 of SEQ ID NO: 1. Alternatively, the anti-TNF-? antibody may be adalimumab or a fragment or variant thereof. In this case, the modification may be one that inhibits presentation of the antibody by DQA1*05:05/DQB1*03:01. Also provided are nucleic acid sequences that encode an antibody according to the invention, and pharmaceutical composition comprising an antibody or nucleic acid sequence of the invention.

Abstract: There are disclosed inter alia polypeptides and nucleic acids encoding said polypeptides which are useful in the treatment, prevention and diagnosis of cancer, particularly melanoma, especially cutaneous melanoma and uveal melanoma.